Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Rhea-AI Summary
Orchestra BioMed (Nasdaq: OBIO) announced that Chairman and CEO David Hochman is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 9:00 a.m. ET in New Hope, Pennsylvania. The company also plans to host one-on-one investor meetings that day.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 20 | Healthcare conference | Neutral | -2.2% | Wells Fargo conference presentation and one-on-one investor meetings were announced. |
| Aug 10 | Q2 earnings report | Neutral | -1.8% | Quarterly results included program updates, strategic capital, and a reported net loss. |
| Jun 29 | Index inclusion | Positive | +12.0% | OBIO joined the Russell 3000 and Russell 2000 indexes. |
| Jun 02 | Inducement grants | Negative | -1.3% | Stock options covering 85,500 common shares were granted to five employees. |
| May 19 | Healthcare conference | Neutral | +0.5% | Jefferies conference participation and investor meetings were announced. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The two recent conference-participation notices preceded negative 24-hour reactions, while other news reactions ranged from -1.28% to +12.03%.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, Sept. 16, 2026 at 9:00am ET, and will also host one-on-one meetings with investors that day.
About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.
Investor Contact:
Silas Newcomb
Orchestra BioMed
snewcomb@orchestrabiomed.com
Media Contact:
Nina Premutico
Orchestra BioMed
npremutico@orchestrabiomed.com
